Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Colorectal Neoplasms 56Ovarian Neoplasms 35Carcinoma, Hepatocellular 35Neoplasms 25Fallopian Tube Neoplasms 20Carcinoma, Non-Small-Cell Lung 19Endometrial Neoplasms 13Glioblastoma 11Breast Neoplasms 11Brain Neoplasms 11Neoplasm Metastasis 9Colonic Neoplasms 9Lung Neoplasms 8Uterine Cervical Neoplasms 7Liver Neoplasms 7Rectal Neoplasms 6Glioma 6Biliary Tract Neoplasms 6Stomach Neoplasms 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Gastrointestinal Neoplasms 4Digestive System Neoplasms 4Carcinoma, Ovarian Epithelial 4Small Cell Lung Carcinoma 3Sarcoma 3Recurrence 3Peritoneal Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3

Interventions

Paclitaxel 6Mitomycin 3Carboplatin 3Bevacizumab 3sodium thiosulfate 2Laparoscopy 2Hyperthermic Intraperitoneal Chemotherapy 2Cisplatin 2relacorilant 1pembrolizumab 1oregovomab 1olaparib 1nilotinib 1liposomal doxorubicin 1Topotecan 1Taxes 1Standard of Care 1Specimen Handling 1Saline Solution 1Practice Guidelines as Topic 1Pancreatectomy 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Laparotomy 1Glucose 1Gemcitabine 1Fluorouracil 1Electrocardiography 1Doxorubicin 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Peritoneal Neoplasms × Bevacizumab × 90 days × Clear all
NCT07213804 2026-05-27

FRAmework-01

Eli Lilly and Company

Phase 3 Recruiting
1,080 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms

NCT03740165 2026-05-04

KEYLYNK-001

Merck Sharp & Dohme LLC

Phase 3 Completed
1,367 enrolled 29 charts
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT06906341 2026-04-14

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Corcept Therapeutics

Phase 2 Recruiting
270 enrolled
Gynecologic

Fallopian Tube Diseases, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡